Paolo Castelnuovo Selected Research

Paolo Castelnuovo Research Topics

Disease

31	Neoplasms (Cancer) 01/2024 - 01/2010
9	Hemorrhage 01/2021 - 03/2009
6	Olfactory Esthesioneuroblastoma (Esthesioneuroblastoma) 06/2022 - 09/2007
5	Rhinosinusitis 06/2023 - 12/2020
5	Nasal Polyps (Nasal Polyp) 06/2023 - 11/2016
5	Adenocarcinoma 01/2019 - 05/2015
4	Asthma (Bronchial Asthma) 12/2022 - 03/2012
4	Cerebrospinal Fluid Leak 01/2021 - 04/2006
3	Melanoma (Melanoma, Malignant) 11/2023 - 08/2013
3	Granuloma 07/2022 - 11/2013
3	COVID-19 11/2020 - 01/2020
2	Obstructive Sleep Apnea 12/2023 - 11/2021
2	Margins of Excision 01/2022 - 06/2016
2	Carcinoma (Carcinomatosis) 10/2021 - 01/2018
2	Pathologic Constriction (Stenosis) 05/2021 - 02/2004
2	Headache (Headaches) 02/2021 - 01/2021
2	Adenoid Cystic Carcinoma (Cylindroma) 01/2021 - 01/2020
2	Adenoma (Adenomas) 11/2019 - 02/2014
2	Pituitary Neoplasms (Pituitary Adenoma) 11/2019 - 02/2014
2	Epistaxis (Nosebleed) 06/2018 - 03/2009
2	Diplopia (Double Vision) 02/2016 - 02/2014
2	Cicatrix (Scar) 08/2012 - 02/2004
1	Neoplasm Metastasis (Metastasis) 08/2023
1	Vision Disorders (Hemeralopia) 08/2023
1	Rare Diseases (Rare Disease) 04/2023
1	Lymphadenopathy 01/2023
1	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 01/2023
1	Chronic Urticaria 12/2022
1	Allergic Rhinitis 10/2021
1	Hiccup (Hiccups) 02/2021
1	Paresthesia (Dysesthesia) 02/2021
1	Thinness 01/2021
1	Necrosis 01/2021
1	Infections 01/2021
1	Mucocele 01/2021
1	Osteoradionecrosis 01/2021
1	Alopecia (Baldness) 01/2021
1	Disease Progression 01/2020
1	Pituitary ACTH Hypersecretion 11/2019
1	Prolactinoma (Prolactinomas) 11/2019
1	Wounds and Injuries (Trauma) 02/2019
1	Sarcoma (Soft Tissue Sarcoma) 01/2018

Drug/Important Bio-Agent (IBA)

3	CholesterolIBA 07/2022 - 11/2013
2	Messenger RNA (mRNA)IBA 12/2023 - 01/2019
2	mepolizumabIBA 06/2023 - 08/2022
2	Biomarkers (Surrogate Marker)IBA 07/2022 - 01/2022
2	somatostatin receptor 2IBA 01/2022 - 01/2018
2	Monoclonal AntibodiesIBA 10/2021 - 12/2020
2	Hormones (Hormone)IBA 11/2019 - 11/2010
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2024
1	Interleukin-8 (Interleukin 8)IBA 12/2023
1	Interleukin-6 (Interleukin 6)IBA 12/2023
1	Immune Checkpoint InhibitorsIBA 08/2023
1	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2023
1	mesoglycanIBA 04/2023
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2023
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2023
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2023
1	Omalizumab (Xolair)FDA Link 12/2022
1	Immunoglobulin E (IgE)IBA 12/2022
1	Transcription Factors (Transcription Factor)IBA 06/2022
1	TESIBA 01/2022
1	CatecholaminesIBA 11/2021
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2021
1	PlatinumIBA 01/2020
1	Dihydrotachysterol (AT 10)IBA 01/2020
1	Growth Hormone (Somatotropin)IBA 11/2019
1	A 17 (A-17)IBA 01/2019
1	ethyl 1- ribofuranosyl- 1,2,4- triazole- 3- carboximidateIBA 01/2019
1	Temazepam (Nocturne)FDA LinkGeneric 08/2018
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2018
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2018

Therapy/Procedure

11	Therapeutics 01/2023 - 09/2013
8	Craniotomy 08/2023 - 04/2006
5	Radiotherapy 01/2021 - 09/2007
4	Drug Therapy (Chemotherapy) 02/2020 - 06/2016
3	Adjuvant Radiotherapy 01/2022 - 05/2015
3	Surgical Flaps 01/2021 - 01/2018
3	Stents 01/2021 - 06/2009
3	Emergency Treatment 02/2019 - 03/2009
2	Endovascular Procedures 01/2021 - 02/2019
2	Combined Modality Therapy 01/2021 - 11/2017
2	Endoscopes 01/2021 - 11/2010
2	Induction Chemotherapy 01/2020 - 11/2017
2	Contraindications 05/2012 - 02/2004
1	Heavy Ion Radiotherapy 11/2023
1	Immunotherapy 01/2022
1	Chemoradiotherapy 01/2022
1	Nasal Surgical Procedures 05/2021
1	Ventriculostomy 02/2021
1	Reoperation 01/2021
1	Biological Therapy 12/2020
1	Ambulatory Care (Outpatient Care) 11/2020
1	Treatment Delay 07/2020
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 02/2020
1	Tracheostomy 01/2020
1	Artificial Respiration (Mechanical Ventilation) 01/2020
1	Salvage Therapy 01/2020
1	Surgical Instruments (Clip) 03/2019
1	Ligation 06/2018